Compare LAES & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAES | ATYR |
|---|---|---|
| Founded | 2022 | 2005 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.0M | 79.2M |
| IPO Year | N/A | 2015 |
| Metric | LAES | ATYR |
|---|---|---|
| Price | $3.73 | $0.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $6.50 | ★ $8.75 |
| AVG Volume (30 Days) | ★ 9.3M | 2.1M |
| Earning Date | 12-11-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,978,000.00 | $190,000.00 |
| Revenue This Year | $66.73 | N/A |
| Revenue Next Year | $92.76 | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.99 | $0.64 |
| 52 Week High | $9.50 | $7.29 |
| Indicator | LAES | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 38.46 | 55.62 |
| Support Level | $3.83 | $0.70 |
| Resistance Level | $4.76 | $0.75 |
| Average True Range (ATR) | 0.32 | 0.05 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 2.23 | 76.89 |
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.